
Struggling with hairfall? Doctor reveals it could be the early symptom of 4 underlying health issues
ALSO READ: Is stress one of the main triggers of hairfall? 8 tips to protect your hair
Dr Debraj Shome, Director & Co-Founder, The Esthetic Clinics (TEC) addressed this concern and told HT Lifestyle about the connection between hair health and systemic wellness.
He said, 'Hair follicles are among the most metabolically active structures in the human body, requiring a steady supply of nutrients, hormones, and oxygen to maintain their rapid growth cycle. When the body faces physiological stress, hair follicles are sometimes the first to suffer, making hair loss a potential early warning system for various medical conditions, such as diabetes, hormonal problems, stress, depression, poor nutrition, vitamin deficiencies, and thyroid disorders, to name a few.'
So this raises a very valid point that your hair loss is not always a cosmetic concern, but a very well body's first distress signals, reminding the need to search for deeper root causes to these otherwise common problems.
Dr Debraj Shome listed out the 4 possible health issues that may be the root causes of hairfall:
1. Iron deficiency
One of the most common causes of chronic hair fall in Indian women is iron deficiency, often without anaemia.
Even marginal drops in ferritin, a protein that stores iron, can push the follicles into dormancy.
Studies have shown that low ferritin levels correlate with more severe telogen effluvium, particularly in menstruating women and those with restrictive diets.
2. Thyroid dysfunction
Thinning of the scalp is another sign.(Shutterstock)
Thyroid hormones control the growth, differentiation, metabolism, and thermogenesis of body cells, making the thyroid-hair connection particularly significant.
Studies show that alopecia is a symptom in approximately 50% of people who experience hyperthyroidism and 33% of those with hypothyroidism.
The pattern typically manifests as diffuse thinning across the scalp, affecting both men and women equally.
3. Autoimmune diseases
Hair loss can also be the body's way of signalling autoimmune activity.
Alopecia areata, an immune-mediated condition, presents as smooth, coin-shaped patches of hair loss and is often associated with conditions like vitiligo, lupus, or Hashimoto's thyroiditis.
4. Cardiovascular links
In men, early-onset androgenetic alopecia has been linked to increased risk of metabolic syndrome and heart disease.
A 2025 study published in the Journal of Medical Sciences and Health found that early onset androgenetic alopecia can be a clinical marker of cardiovascular issues such as metabolic syndrome, atheromatous plaques, hypertension, obesity and hyperlipidemia.
As you go for a doctor's checkup, it is important to identify the timeline of the hairfall, as it would act as a valuable clue for understanding the deeper root causes. Dr Debraj Shome emphasised the value of timing.
He said, ' Hair's strength lies in its timing. Its reaction is often delayed by weeks or even months, which makes it an excellent retrospective clue. For example, when a patient presents with hair shedding in March, the trigger often occurred in January. This can be an illness, weight loss, a medication, or even emotional trauma. The follicles respond slowly, but visibly. This delayed feedback loop is why thorough history-taking matters so much. A scalp may tell us that something is wrong, but only a systemic lens reveals what that is and how we can work to fix it.'
He also gave a heads-up that dermatologists ask not just about recent haircare but also about sleep patterns, stress levels, nutrition, menstrual history, thyroid symptoms, and gut health, which help them arrive at a comprehensive evaluation. The evaluation also includes tests like thyroid function tests, complete blood count, iron studies, vitamin D levels, and hormonal panels.
Note to readers: This article is for informational purposes only and not a substitute for professional medical advice. Always seek the advice of your doctor with any questions about a medical condition.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

The Hindu
15 minutes ago
- The Hindu
AINU launches new centre in Hyderabad covering various sub-specialities
The Asian Institute of Nephrology and Urology (AINU), launched its new centre in Banjara Hills here on Monday. The hospital has a capacity of 150 beds. The centre features four operating rooms, 34 dialysis stations and advanced robotic surgical technology, enabling complex urology and nephrology procedures with greater precision. The hospital also has eight centres of excellence, covering sub-specialities such as female urology, uro-oncology and robotic surgery, paediatric urology, reconstructive urology and andrology. The burden of urological diseases is rising sharply in India due to lifestyle disorders such as hypertension, obesity and diabetes, coupled with increased life expectancy. 'Prostate cancer is now the second most common cancer among Indian men, growing at 2.5% annually, and 50 to 60% of men over 60 suffer from benign prostatic enlargement,' said AINU manging director Mallikarjuna. He added that 25 years ago, urology was largely limited to treating kidney stones and enlarged prostates. Today, the scope includes advanced cancer care, complex reconstructions, paediatric interventions, female urology and robotic surgeries. 'One doctor cannot be perfect in every area, so we have created dedicated teams focused solely on one sub-speciality, performing the same surgeries repeatedly. This results in faster procedures, fewer complications, better outcomes and ultimately lower costs for patients,' he added.


Economic Times
an hour ago
- Economic Times
India clears Roche's 7-minute cancer injection Tecentriq for patients, with Phase IV trial condition
Synopsis Roche has received clearance to import and market Atezolizumab injection (Tecentriq) for subcutaneous administration in India, potentially reducing cancer treatment time and costs. The approval, granted by a technical committee, requires Roche to conduct a Phase IV clinical trial in India. This new route offers a faster, more convenient option for patients, with administration possible outside of hospitals. Roche Gets Approval to Import Key Cancer Injection for Domestic Mkt New Delhi: The technical committee constituted for supervising clinical trials on new chemical entities has cleared Swiss drug major Roche to import and market cancer drug Atezolizumab injection (Tecentriq) through subcutaneous (SC) route-under the skin injection for Indian decisions is expected to provide relief to patients in the contry as the new subcutaneous injections will cut treatment time to nearly seven minutes from the 30-60 minutes in the standard intravenous (IV) infusion, besides saving on costs. The panel's permission has been given with a condition that the company would conduct a Phase IV clinical trial in India. "Switching from intravenous (IV) to subcutaneous (SC) administration of Atezolizumab can potentially reduce costs due to decreased healthcare professional time and improved patient convenience," a government official told ET. "Tecentriq may be administered by a healthcare professional outside of the hospital, in a community care setting or at a patient's home," he added. Atezolizumab is an immunotherapy called an immune checkpoint inhibitor, which blocks the immune system's natural brakes to help immune cells fight technical committee under the Director General of Health Services (DGHS) was formed in 2013 following the directions of the Supreme a recent meeting, Roche presented the proposal for grant of permission to import and market the drug product Atezolizumab injection (Tecentriq®) 1875 mg/15 mL vial for subcutaneous administration for the following indications with the request of local Phase III clinical trial waiver and commitment to conduct a Phase IV trial in is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy. It is a monotherapy for the first line treatment of patients of metastatic committee noted the pharmacokinetic-pharmacodynamic or PK/PD results of Asian & non-Asian population from the global clinical study for the ethnic differences in the PK parameters in the study. The committee further noted that firm has received the USFDA approval for the SC route on committee also asked the company to submit Phase IV clinical trial protocol to CDSCO within three months of grant of marketing authorisation.


Time of India
an hour ago
- Time of India
India clears Roche's 7-minute cancer injection Tecentriq for patients, with Phase IV trial condition
New Delhi: The technical committee constituted for supervising clinical trials on new chemical entities has cleared Swiss drug major Roche to import and market cancer drug Atezolizumab injection ( Tecentriq ) through subcutaneous (SC) route-under the skin injection for Indian patients. The decisions is expected to provide relief to patients in the contry as the new subcutaneous injections will cut treatment time to nearly seven minutes from the 30-60 minutes in the standard intravenous (IV) infusion, besides saving on costs. The panel's permission has been given with a condition that the company would conduct a Phase IV clinical trial in India. "Switching from intravenous (IV) to subcutaneous (SC) administration of Atezolizumab can potentially reduce costs due to decreased healthcare professional time and improved patient convenience," a government official told ET. "Tecentriq may be administered by a healthcare professional outside of the hospital, in a community care setting or at a patient's home," he added. Atezolizumab is an immunotherapy called an immune checkpoint inhibitor, which blocks the immune system's natural brakes to help immune cells fight cancer. The technical committee under the Director General of Health Services (DGHS) was formed in 2013 following the directions of the Supreme Court. In a recent meeting, Roche presented the proposal for grant of permission to import and market the drug product Atezolizumab injection (Tecentriq®) 1875 mg/15 mL vial for subcutaneous administration for the following indications with the request of local Phase III clinical trial waiver and commitment to conduct a Phase IV trial in India. Atezolizumab is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy. It is a monotherapy for the first line treatment of patients of metastatic NSCLC. The committee noted the pharmacokinetic-pharmacodynamic or PK/PD results of Asian & non-Asian population from the global clinical study for the ethnic differences in the PK parameters in the study. The committee further noted that firm has received the USFDA approval for the SC route on 12.09.2024. The committee also asked the company to submit Phase IV clinical trial protocol to CDSCO within three months of grant of marketing authorisation.